Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yow-Ming Wang

Showing results (1-10 of 43) with videos related to

Pageof 5
Sort By:
Clinical Pharmacology and Therapeutics|December 22, 2022
Advancing Innovations in BiosimilarsYow-Ming Wang, David G Strauss
The Journal of Pediatric Pharmacology and Therapeutics : JPPT : the Official Journal of PPAG|May 1, 2014
Pediatric newsChristine Yuen-Yi Hon, Yow-Ming Wang
Clinical Pharmacology and Therapeutics|August 5, 2025
Clinical Pharmacology Characterization of Bispecific T-Cell Engagers: A Summary Based on FDA ApprovalsTing Wang, Yow-Ming Wang, Qin Sun
Bioanalysis|March 23, 2011
Bioanalytical considerations in the comparability assessment of biotherapeuticsJean W Lee, Yow-Ming Wang, Michael Moxness, et al.
Clinical Pharmacology and Therapeutics|September 30, 2022
Pharmacodynamic Biomarkers Evidentiary Considerations for Biosimilar Development and ApprovalDavid G Strauss, Yow-Ming Wang, Jeffry Florian, et al.
Clinical and Translational Science|May 25, 2022
Changing the drug development and therapeutic paradigm with biologic drug combinations and bispecifics: How to choose between these two approaches?Songmao Zheng, Rodney Prell, Jennifer Sheng, et al.
Clinical Pharmacology and Therapeutics|September 8, 2020
Elucidating the Impact of Immunogenicity Assessment Postapproval: A Targeted Analysis of Immunogenicity Postmarketing Requirements and CommitmentsDaphne Guinn, Rajanikanth Madabushi, Yow-Ming Wang, et al.
Therapeutic Innovation & Regulatory Science|December 1, 2020
Communicating Immunogenicity-Associated Risk in Current U.S. FDA Prescription Drug Labeling: A Systematic EvaluationDaphne Guinn, Rajanikanth Madabushi, Yow-Ming Wang, et al.
Pharmaceutical Research|December 20, 2012
Pharmacokinetic and pharmacodynamic modeling of romiplostim in animalsWojciech Krzyzanski, Liviawati Sutjandra, Juan Jose Perez-Ruixo, et al.
Clinical Pharmacology and Therapeutics|June 13, 2019
Effect of Body Weight on Risk-Benefit and Dosing Regimen Recommendation of Secukinumab for the Treatment of Moderate to Severe Plaque PsoriasisJee Eun Lee, Jie Wang, Jeffry Florian, et al.
Pageof 5

Showing results (1-10 of 43) with videos related to

Sort By:
Pageof 5
Clinical Pharmacology and Therapeutics|December 22, 2022
Advancing Innovations in BiosimilarsYow-Ming Wang, David G Strauss
The Journal of Pediatric Pharmacology and Therapeutics : JPPT : the Official Journal of PPAG|May 1, 2014
Pediatric newsChristine Yuen-Yi Hon, Yow-Ming Wang
Clinical Pharmacology and Therapeutics|August 5, 2025
Clinical Pharmacology Characterization of Bispecific T-Cell Engagers: A Summary Based on FDA ApprovalsTing Wang, Yow-Ming Wang, Qin Sun
Bioanalysis|March 23, 2011
Bioanalytical considerations in the comparability assessment of biotherapeuticsJean W Lee, Yow-Ming Wang, Michael Moxness, et al.
Clinical Pharmacology and Therapeutics|September 30, 2022
Pharmacodynamic Biomarkers Evidentiary Considerations for Biosimilar Development and ApprovalDavid G Strauss, Yow-Ming Wang, Jeffry Florian, et al.
Clinical and Translational Science|May 25, 2022
Changing the drug development and therapeutic paradigm with biologic drug combinations and bispecifics: How to choose between these two approaches?Songmao Zheng, Rodney Prell, Jennifer Sheng, et al.
Clinical Pharmacology and Therapeutics|September 8, 2020
Elucidating the Impact of Immunogenicity Assessment Postapproval: A Targeted Analysis of Immunogenicity Postmarketing Requirements and CommitmentsDaphne Guinn, Rajanikanth Madabushi, Yow-Ming Wang, et al.
Therapeutic Innovation & Regulatory Science|December 1, 2020
Communicating Immunogenicity-Associated Risk in Current U.S. FDA Prescription Drug Labeling: A Systematic EvaluationDaphne Guinn, Rajanikanth Madabushi, Yow-Ming Wang, et al.
Pharmaceutical Research|December 20, 2012
Pharmacokinetic and pharmacodynamic modeling of romiplostim in animalsWojciech Krzyzanski, Liviawati Sutjandra, Juan Jose Perez-Ruixo, et al.
Clinical Pharmacology and Therapeutics|June 13, 2019
Effect of Body Weight on Risk-Benefit and Dosing Regimen Recommendation of Secukinumab for the Treatment of Moderate to Severe Plaque PsoriasisJee Eun Lee, Jie Wang, Jeffry Florian, et al.
Pageof 5